SciBase Holding AB (OSTO:SCIB) ROCE % : -177.63% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SciBase Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SciBase Holding AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -177.63%.

SciBase Holding AB ROCE % Historical Data

The historical data trend for SciBase Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciBase Holding AB ROCE % Chart

SciBase Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-83.24

-69.78

-84.61

-135.80

-142.36

SciBase Holding AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-118.28	-107.57	-132.60	-121.82	-177.63

SciBase Holding AB ROCE % Calculation

SciBase Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-60.827	/	( ( (64.334 - 17.099)	+	(61.731 - 23.511) )	/ 2 )
	=	-60.827	/	( (47.235	+	38.22)	/ 2 )
	=	-60.827	/	42.7275
	=	-142.36 %

SciBase Holding AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-69.52	/	( ( (56.079 - 16.025)	+	(61.731 - 23.511) )	/ 2 )
	=	-69.52	/	( ( 40.054	+	38.22 )	/ 2 )
	=	-69.52	/	39.137
	=	-177.63 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

SciBase Holding AB (OSTO:SCIB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SciBase Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of SciBase Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SciBase Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SciBase Holding AB (OSTO:SCIB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Landsvagen 39, Sundbyberg, Stockholm, SWE, 172 63

Website

https://www.scibase.com

SciBase Holding AB is a medical technology company that develops devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's products include Nevisense and Nevisense Go and to date, the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. It is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. The company operates in two segments which includes skin cancer and skin barrier assessment. Majority of the revenue is generated from skin cancer segment. Its geographical segments are Europe/Rest of the World, the United States/North America, and Asia/Oceania.

SciBase Holding AB Headlines

No Headlines